ARCOMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.5 SEK | +3.05% |
|
-1.11% | +68.55% |
| 25/04 | Arcoma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 29/01 | Arcoma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.91 for the current period. Therefore, the company is undervalued.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +68.55% | 15.99M | - | ||
| -3.67% | 15.01B | - | ||
| -35.60% | 2.8B | C- | ||
| -12.68% | 2.45B | - | ||
| -9.95% | 1.46B | - | - | |
| -.--% | 1.12B | - | - | |
| +96.67% | 515M | B+ | ||
| +15.33% | 249M | C | ||
| -13.03% | 202M | - | - | |
| +2.59% | 188M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- ARCOMA Stock
- Ratings Arcoma AB